Literature DB >> 8090772

Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.

J H Kordower1, V Charles, R Bayer, R T Bartus, S Putney, L R Walus, P M Friden.   

Abstract

Intrastriatal injections of quinolinic acid induce a pattern of neuronal degeneration similar to that seen in Huntington disease. In the present study, nerve growth factor (NGF) crossed the blood-brain barrier in a dose-dependent fashion following intravenous infusion when conjugated to an antibody directed against the transferrin receptor (OX-26). Intravenous injections of the OX-26-NGF conjugate selectively prevented the loss of striatal choline acetyltransferase-immunoreactive neurons which normally occurs following quinolinic acid administration relative to control rats receiving vehicle or a nonconjugated mixture of OX-26 and NGF. These data demonstrate that a neurotrophic factor-antibody conjugate can prevent the degeneration of central NGF-responsive neurons following systemic administration.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8090772      PMCID： PMC44750          DOI： 10.1073/pnas.91.19.9077

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  25 in total

1.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids.

Authors:  J M Schumacher; M P Short; B T Hyman; X O Breakefield; O Isacson
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial.

Authors:  L Olson; E O Backlund; T Ebendal; R Freedman; B Hamberger; P Hansson; B Hoffer; U Lindblom; B Meyerson; I Strömberg
Journal:  Arch Neurol       Date:  1991-04

4.  Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain.

Authors:  E J Mufson; M Bothwell; J H Kordower
Journal:  Exp Neurol       Date:  1989-09       Impact factor: 5.330

5.  Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).

Authors:  L Olson; A Nordberg; H von Holst; L Bäckman; T Ebendal; I Alafuzoff; K Amberla; P Hartvig; A Herlitz; A Lilja
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

6.  Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones.

Authors:  S W Davies; K Beardsall
Journal:  Neurosci Lett       Date:  1992-06-22       Impact factor: 3.046

Review 7.  Function and evolution in the NGF family and its receptors.

Authors:  T Ebendal
Journal:  J Neurosci Res       Date:  1992-08       Impact factor: 4.164

8.  NGF receptor (p75)-immunoreactivity in the developing primate basal ganglia.

Authors:  J H Kordower; E J Mufson
Journal:  J Comp Neurol       Date:  1993-01-15       Impact factor: 3.215

9.  Blood-brain barrier penetration and in vivo activity of an NGF conjugate.

Authors:  P M Friden; L R Walus; P Watson; S R Doctrow; J W Kozarich; C Bäckman; H Bergman; B Hoffer; F Bloom; A C Granholm
Journal:  Science       Date:  1993-01-15       Impact factor: 47.728

Review 10.  Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases.

Authors:  F Hefti; J Hartikka; B Knusel
Journal:  Neurobiol Aging       Date:  1989 Sep-Oct       Impact factor: 4.673
View more
  14 in total

1.  Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.

Authors:  K D Anderson; N Panayotatos; T L Corcoran; R M Lindsay; S J Wiegand
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain.

Authors:  A Martínez-Serrano; W Fischer; S Söderström; T Ebendal; A Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 3.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

4.  Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging.

Authors:  A Martínez-Serrano; A Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 5.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

6.  Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.

Authors:  A Martínez-Serrano; A Björklund
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

7.  Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length.

Authors:  A J Cooper; K R Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

8.  Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.

Authors:  D F Emerich; M D Lindner; S R Winn; E Y Chen; B R Frydel; J H Kordower
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

9.  Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.

Authors:  W F Goins; K A Lee; J D Cavalcoli; M E O'Malley; S T DeKosky; D J Fink; J C Glorioso
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.